A5100672886- Retinal and Optic Conditions
- Cerebral Venous Sinus Thrombosis
- CAR-T cell therapy research
- Synthesis and Biological Evaluation
- Multiple Myeloma Research and Treatments
- Particle physics theoretical and experimental studies
- advanced mathematical theories
- High-Energy Particle Collisions Research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Mental Health and Psychiatry
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Neuroscience and Neuropharmacology Research
- Viral-associated cancers and disorders
- Amino Acid Enzymes and Metabolism
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Particle Detector Development and Performance
- Ion Channels and Receptors
- Nanowire Synthesis and Applications
- Quinazolinone synthesis and applications
- Bioactive Compounds and Antitumor Agents
- Receptor Mechanisms and Signaling
- Advanced Semiconductor Detectors and Materials
Sanofi (United States)
2024
University of California, Berkeley
2024
Johns Hopkins University
2002-2018
IFC Research (United Kingdom)
2018
Online Technologies (United States)
2018
University of California, San Diego
2005-2016
National Cancer Institute
2014
National Institutes of Health
2013-2014
Center for Cancer Research
2014
Emory University
2010
Serine racemase (SR), localized to astrocytic glia that ensheathe synapses, converts l -serine d -serine, an endogenous ligand of the NMDA receptor. We report activation SR by glutamate neurotransmission involving α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors via receptor interacting protein (GRIP) and physiologic regulation cerebellar granule cell migration SR. GRIP physiologically binds SR, augmenting activity release. infection neonatal mouse cerebellum in vivo enhances...
Transient receptor potential ankyrin-1 (TRPA1) and transient vanilloid-1 (TRPV1) are calcium (Ca2+)-permeable ion channels mostly known as pain receptors in sensory neurons. However, growing evidence suggests their crucial involvement the pathogenesis of IBD. We explored possible contribution TRPA1 TRPV1 to T-cell-mediated colitis.We evaluated role Trpa1 gene deletion two models experimental colitis (ie, interleukin-10 knockout T-cell-adoptive transfer models). performed electrophysiological...
ABSTRACT The ORF74 or vGCR gene encoded by Kaposi's sarcoma-associated herpesvirus (KSHV; also called human 8) has properties of a ligand-independent membrane receptor signaling protein with angiogenic that is predicted to play key role in the biology virus. We have examined expression mRNA and primary effusion lymphoma (PEL) cell lines, PEL multicentric Castleman's disease (MCD) tumors, sarcoma lesions infected endothelial cultures. proved be expressed lines as large spliced bicistronic 3.2...
Kaposi's sarcoma (KS)-associated herpesvirus (KSHV; also called human 8) is believed to be the etiologic agent of sarcoma, multicentric Castleman's disease, and AIDS-associated primary effusion lymphoma. KSHV infection dermal microvascular endothelial cells (DMVEC) in culture results conversion cobblestone-shaped spindle-shaped cells, a characteristic morphological feature KS lesions. All KSHV-infected DMVEC cultures express latency-associated nuclear protein LANA1, subfraction these undergo...
Abstract : Dopamine receptor activation regulates cyclic AMP levels and is critically involved in modulating neurotransmission the striatum. Others have shown that α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionate (AMPA)‐type glutamate receptor‐mediated current potentiated by AMP‐dependent protein kinase (PKA) activation. We made whole‐cell patch clamp recordings from cultured striatal neurons tested whether D1‐type dopamine affected AMPA currents. After a 5‐min exposure to D1 agonist SKF...
Abstract T cell costimulation via OX40 is known to increase CD4+ expansion and effector function enhances the development of memory. can also prevent, even reverse, anergy. However, role in CD8+ less well defined, particularly setting immune tolerance. To determine effects on induction host repertoire an endogenous tumor Ag, we examined fate cells specific for immunodominant rat HER-2/neu epitope, RNEU420–429, FVB MMTV-neu (neu-N) mice, which express protein a predominantly...
The pathogenic nature of cancer is attributed, at least in part, to the ability tumors cells induce systemic and local mechanisms immune tolerance. However, we previously reported that tumor-free survival up 100% tolerized HER-2/neu transgenic mice can be achieved by administration neu-specific mAb concurrently with a HER-2/neu-expressing, GM-CSF-secreting whole cell vaccine. In this report, show one mechanism improved antitumor activity induced combination these 2 neu-targeted interventions...
Abstract T cell–engaging antibodies (TCEs) are showing promising efficacy in relapsed/refractory multiple myeloma, even patients that relapsed after B-cell maturation antigen (BCMA)-targeted therapy. Patients with myeloma may have compromised T-cell health unaccounted for by preclinical models. Here, we use Myeloma Drug Sensitivity Testing (My-DST) ex vivo measurement of anti-multiple cytotoxicity the trispecific CD38/CD28xCD3 TCE SAR442257 through activation patients’ own endogenous cells...
Bcl-2 inhibitors are currently being evaluated in clinical studies for treatment of patients with solid tumors and hematopoietic malignancies. In this study we explored the potential combining pan-Bcl-2 inhibitor GX15-070 (GX15; obatoclax) immunotherapeutic modalities. We vitro effects GX15 on human T cell subsets obtained from PBMCs terms activation, memory, suppressive function. Our results indicated that healthy-donor PBMCs, mature-activated cells were more resistant to than...
Current treatment strategies for multiple myeloma (MM) are highly effective, but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD3xCD28 trispecific antibody SAR442257 targets CD38 and CD28 on MM cells co-stimulates CD3 T (TCs). We evaluated different key aspects such as avidity interaction, tumor killing, biomarkers drug potency in three distinct cohorts of RRMM patients. found that a significantly higher proportion (86%) exhibited aberrant co-expression compared to...
Abstract A band filter gradient structure was obtained in porous Si by electrochemically etching a rugate into wafer using an asymmetrically placed counter electrode. The resulting film displays rejection whose wavelength maximum varies spatially due to the uneven distribution of current across during etch. rainbow‐like can be converted SiO 2 graded thermal oxidization. robust and flexible composite silicone/porous silicon is achieved impregnation with silicone polymer. (© 2005 WILEY‐VCH...
An exploration of the immunotherapeutic potential pan-Bcl-2 inhibitor GX15–070 (GX15) has revealed that early-activated T cells derived from human peripheral blood are more sensitive to GX15 than prolonged-activated cells. Furthermore, non-memory and regulatory also exhibit higher sensitivity GX15. The implication these prior findings suggests may enhance efficacy immunotherapies in clinical settings.
<div>Abstract<p>T cell–engaging antibodies (TCEs) are showing promising efficacy in relapsed/refractory multiple myeloma, even patients that relapsed after B-cell maturation antigen (BCMA)-targeted therapy. Patients with myeloma may have compromised T-cell health unaccounted for by preclinical models. Here, we use Myeloma Drug Sensitivity Testing (My-DST) <i>ex vivo</i> measurement of anti-multiple cytotoxicity the trispecific CD38/CD28xCD3 TCE SAR442257 through...
There is accumulating evidence of BCMA and GPRC5D loss after treatment with T-cell redirecting therapies in patients relapsed/refractory multiple myeloma (RRMM). While complete CD38 not observed upon relapses anti-CD38 monoclonal antibodies (mAb), there downregulation surface expression decreased number function NK cells, which renders these resistant to retreatment mAb. Here, we provide preclinical that RRMM previously exposed mAb could benefit from T-cell-based immunotherapy depend less on...
<p>Ratio of CD8+ to CD4+ T cells does not appear affect sensitivity SAR442257</p>
<p>The percentage of MM cells CD28+ does not appear to affect sensitivity SAR442257</p>
<p>Sensitivity to SAR4422557 across treatment groups</p>
<p>Ratio of CD8+ to CD4+ T cells does not appear affect sensitivity SAR442257</p>
<p>The percentage of MM cells CD28+ does not appear to affect sensitivity SAR442257</p>
<p>CD38 expression across treatment groups</p>
<div>Abstract<p>T cell–engaging antibodies (TCEs) are showing promising efficacy in relapsed/refractory multiple myeloma, even patients that relapsed after B-cell maturation antigen (BCMA)-targeted therapy. Patients with myeloma may have compromised T-cell health unaccounted for by preclinical models. Here, we use Myeloma Drug Sensitivity Testing (My-DST) <i>ex vivo</i> measurement of anti-multiple cytotoxicity the trispecific CD38/CD28xCD3 TCE SAR442257 through...
<p>Multi-epitope CD38-FITC binds CD38 in cells treated with SAR442257.</p>